Article Sidebar

pdf
Date Published: 17/10/2024
Abstract Views: 308
Views pdf: 238
DOI: https://doi.org/10.51298/vmj.v543i2.11384
Issue
Vol. 543 No. 2 (2024)
Section
Các bài báo
How to Cite
Phạm, V. D., Nguyễn, V. L., Trịnh , L. H., Nguyễn, T. P. T., Nguyễn, T. N., Trương, T. T. H., Hoàng, P. Q. T., Trần, H. P., Nguyễn, H. H., & Đặng, T. T. H. (2024). EVALUATION THE TREATMENT OUTCOME OF POTENTIALLY RESECTABLE COLORETAL CANCER LIVER METASTASES AT MILITARY CENTRAL HOSPITAL 108. Vietnam Medical Journal, 543(2). https://doi.org/10.51298/vmj.v543i2.11384

EVALUATION THE TREATMENT OUTCOME OF POTENTIALLY RESECTABLE COLORETAL CANCER LIVER METASTASES AT MILITARY CENTRAL HOSPITAL 108

Văn Dũng Phạm, Việt Long Nguyễn, Lê Huy Trịnh , Thị Phương Thảo Nguyễn, Thanh Ngọc Nguyễn, Thị Thảo Hiền Trương, Phan Quỳnh Trang Hoàng, Hoàng Phương Trần, Huy Hoàng Nguyễn, Thị Thu Hiền Đặng

Main Article Content

Abstract

Objectives: Evaluate treatment outcome in potentially resectable liver metastases coloretal cancer patients with combined chemotherapy and targeted drugs. Patients and methods: Combined retrospective and prospective study on 41 colorectal cancer with liver metastasis patients underwent combination chemotherapy with targeted drugs at Chemotherapy department, Military Central Hospital 108 between January 2020 and March 2024. Results: Mean age was 58,7 ± 12,8 (31-80). Male/Female ratio = 2,73/1. The overall response rate (ORR) was 80%, Successful conversion rate was 60.9%. The most common side effect was hepatic toxicity, neutropenia and neurotoxicity were mainly mild grade 1-2. Conclusions: Chemotherapy combined with targeted drugs of patients with colorectal cancer with liver metastases resulted in high response rate, feasible and tolerable toxicity.

Article Details

Keywords

Colorectal cancer.

References

1. Nguyễn Văn Hiếu (2015), Ung thư học, Nhà xuất bản y học, Hà nội.
2. Đỗ Huyền Nga (2018) Đánh giá kết quả hóa trị phác đồ FOLFOX4 kết hợp bevacizumab trong ung thư đại trực tràng di căn, Luận án tiến sĩ y học, Đại Học Y Hà Nội
3. Manfredi. S, Lepage C, Hatem. C et al. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg, 2006, 244 (2), 254-259.
4. Milburn Jessup, Lamar S, McGinis Glenn D et al. The National Cancer Data Base. Report on colon cancer. Cancer 1996;78:918–26.
5. Leporrier. J, Maurel. J, Chiche. L et al. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg, 2006, 93 (4), 465-474.
6. Wade. T. P, Virgo. K. S, Li. M. J et al. Outcomes after detection of metastatic carcinoma of the colon and rectum in a national hospital system. J Am Coll Surg, 1996, 182 (4), 353-361.
7. C Villard 1, M Habib 2. Conversion therapy in patients with colorectal liver metastases. European Journal of Surgical Oncology August 2021.
8. Rui Ma,1 Tao Li2. Conversion therapy combined with individualized surgical treatment strategy improves survival in patients with colorectal cancer liver metastases. Int J Clin Exp Pathol. 2021; 14(3): 314–321.
9. Garufi C, Torsello A, Tumulo S, Mottolese M, Campanella C, Zeuli M, Lo Re G, Pizzi G, Ettorre GM, Sperduti I. POCHER (preoperative chemotherapy for hepatic resection) study with cetuximab (Cmab) plus CPT-11/5-fluorouracil (5-FU)/ leucovorin (FA)/oxaliplatin (L-OHP) (CPT-11-FFL) in unresectable colorectal liver metastases (CLM) J Clin Oncol. 2009;27:ae15020.